Andrew C.W. Zannettino

Author

Also Known As

A C W Zannettino, A C Zannettino, A Zannettino, A. C. W. Zannettino, A. C.W. Zannettino, A. Zannettino, A.C. Zannettino, A.C.W Zannettino, A.C.W. Zannettino, AC Zannettino

370

Publications

17.5K

Citations

H-Index

150

Concepts

All Affiliations

The University of Adelaide South Australia Pathology South Australian Health and Medical Research Institute Hanson Institute Centre for Cancer Biology

About

Andrew C.W. Zannettino is an author at The University of Adelaide specializing in medicine, cell biology, and regenerative medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	75	6.2K
2	Engineering	15	15	1.9K
3	Health Sciences	15	16	1K
4	Natural Sciences	5	5	512
5	Public Health	1	1	35

Andrew C.W. Zannettino

175

Publications

14.8K

Citations

H-Index

Page 1

	Year	Citations
Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow Stan Gronthos, Andrew C.W. Zannettino, Shelley Hay, Journal of Cell Science Tissue EngineeringEngineeringAdult Stem CellBiomedical EngineeringRegenerative Medicine	2003	1K
Mechanisms of magnesium‐stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants Hala Zreiqat, C. R. Howlett, Andrew C.W. Zannettino, Journal of Biomedical Materials Research	2002	810
Multipotential human adipose‐derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo Andrew C.W. Zannettino, Sharon Paton, Agnieszka Arthur, Journal of Cellular Physiology	2007	540
OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Deborah L. White, Verity A Saunders, Phuong Dang, Blood	2006	430
Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche Michelle A. Lawson, Michelle M. McDonald, Nataša Kovačić, Nature Communications	2015	379
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Deborah L. White, Verity A Saunders, Phuong Dang, Blood	2007	330
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Andrea L. Dewar, Antony C. Cambareri, Andrew C.W. Zannettino, Blood	2005	282
Differential Cell Surface Expression of the STRO-1 and Alkaline Phosphatase Antigens on Discrete Developmental Stages in Primary Cultures of Human Bone Cells Stan Gronthos, Andrew C.W. Zannettino, Stephen E. Graves, Journal of Bone and Mineral Research	1999	280
<i>EZH2</i> and <i>KDM6A</i> Act as an Epigenetic Switch to Regulate Mesenchymal Stem Cell Lineage Specification Sarah Hemming, Dimitrios Cakouros, Sandra Isenmann, Stem Cells Zeste Homology 2Epigenetic ChangeGeneticsAdult Stem CellStem Cell Biology	2013	260
RANKL Expression Is Related to the Differentiation State of Human Osteoblasts Gerald J. Atkins, P. Kostakis, Bei-Qing Pan, Journal of Bone and Mineral Research	2003	250

Page 1